<code id='FC34CEF6A3'></code><style id='FC34CEF6A3'></style>
      • <acronym id='FC34CEF6A3'></acronym>
      <center id='FC34CEF6A3'><center id='FC34CEF6A3'><tfoot id='FC34CEF6A3'></tfoot></center><abbr id='FC34CEF6A3'><dir id='FC34CEF6A3'><tfoot id='FC34CEF6A3'></tfoot><noframes id='FC34CEF6A3'>
      • <optgroup id='FC34CEF6A3'><strike id='FC34CEF6A3'><sup id='FC34CEF6A3'></sup></strike><code id='FC34CEF6A3'></code></optgroup>
        5. <b id='FC34CEF6A3'><label id='FC34CEF6A3'><select id='FC34CEF6A3'><dt id='FC34CEF6A3'><span id='FC34CEF6A3'></span></dt></select></label></b><u id='FC34CEF6A3'></u>
          <i id='FC34CEF6A3'><strike id='FC34CEF6A3'><tt id='FC34CEF6A3'><pre id='FC34CEF6A3'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-10-06 18:32:51 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：98
                                  
                                    
          
                                   
          Editor’s note: A recording of the event is embedded below.
          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
          advertisement
          Featured Speakers
          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          The thinking behind the controversial eating disorder chatbot Tessa
                                
                            
          Next article：  
                                      
                                          Walensky prepares to leave CDC — and Congress — behind
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles